[Morphological features of immune-related cutaneous adverse events associated with anti-PD-1/PD-L1 cancer immunotherapy].

Authors

A Yu Syryseva, E A Shatokhina, I A Pokataev, A A Bobyreva, N V Danilova

Published in

Arkhiv patologii. Volume 88. Issue 4. Pages 20-27.

Abstract

To study the morphological patterns of immune-related cutaneous lesions (irCLs) that occur during antitumor immunotherapy in cancer patients.
The study included 48 patients with the following nosology: malignant neoplasms of the skin and soft tissues - 20 patients (41.7%), malignant neoplasms of the genitourinary system - 13 (27%), malignant neoplasms of the lungs and bronchi - 9 (18.8%), malignant neoplasms of the upper respiratory tract - 5 (10.4%), malignant neoplasms of the gastrointestinal tract - 1 (2.1%), with immune-mediated skin lesions during treatment with pembrolizumab - 25 (52.1%), nivolumab - 18 (37.5%), prolgolimab - 4 (8.3%), avelumab - 1 (2.1%).
Among the irCLs in the study cohort, lichenoid - 14 (29.2%) cases and psoriasiform - 11 cases (22.9%) were predominant, while other morphological variants were significantly less common. IrCL morphologically mimic classic dermatoses, but have distinctive features indicating their drug-induced, immune-related nature.
The study demonstrated that irCLs are clinically significant complications of PD-1/PD-L1 inhibitor therapy. Histological analysis confirmed their immunoinflammatory nature and revealed characteristic morphological changes, emphasizing the importance of routine skin biopsies for optimal patient management.

PMID:
42531238
Bibliographic data and abstract were imported from PubMed on 31 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.